FindTrial
Sign In

A study on the prognosis of malignant tumor of the uterine body predicted by multi-omics

A study on the prognosis of malignant tumor of the uterine body predicted by multi-omics

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500107747
Enrollment
Unknown
Registered
2025-08-18
Start date
2025-09-30
Completion date
Unknown
Last updated
2025-08-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant tumor of the uterine body

Interventions

Malignant tumor of the uterine body group:None

Sponsors

The First Affiliated Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 79 Years

Inclusion criteria

Inclusion criteria: 1. Women aged 18 to 79; 2. Patients diagnosed with malignant tumors of the uterine body through tissue biopsy or pathological examination of surgical specimens; 3. Patients who underwent auxiliary examinations such as pelvic MRI and serological indicators (CA125, HE4, cancer spectrum, etc.) before surgery; 4. Patients with acceptable liver and kidney functions; 5. Patients without other malignant tumors; 6. Patients without mental illness.

Exclusion criteria

Exclusion criteria: 1. Patients who are currently participating in other clinical trials; 2. Patients with severely insufficient original data; 3. Patients without pathological confirmation evidence; 4. Patients with unclear or lost examination results; 5. Patients with blood diseases.

Design outcomes

Primary

MeasureTime frame
Overall survival time;Progression-free survival time;—

Countries

China

Contacts

Public ContactMu Xiaoling

The First Affiliated Hospital of Chongqing Medical University

mxl@hospital.cqmu.edu.cn+86 189 8328 9859

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026